Perception, Awareness, and Acceptance of Human Papillomavirus Disease and Vaccine Among Parents of Boys Aged 9 to 18 Years
NCT01197079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2025-03-28
Summary
The objectives of this study are:
1. to determine the degree of understanding and perceived risks for human papillomavirus (HPV) disease, to examine and assess attitudes for personal use of HPV vaccine and identify potential barriers to HPV vaccine access and utilization in a population of young men who have sex with men (MSM) (under 26 years of age)and in parents of boys aged 9 to 18 years
2. to determine HPV vaccine acceptance and predictors of acceptance in a population of young MSM and in patients of boys ages 9 to 18 years
3. to develop strategies to overcome potential barriers to vaccination and improve vaccine access and utilization via development of targeted educational initiatives.
Conditions
- Human Papillomavirus (HPV)
Interventions
- OTHER
-
Survey
Self administered anonymous survey
Sponsors & Collaborators
-
Ann & Robert H Lurie Children's Hospital of Chicago
lead OTHER
Eligibility
- Min Age
- 9 Years
- Max Age
- 26 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-08-31
- Primary Completion
- 2013-09-30
- Completion
- 2016-12-31
Countries
- United States
Study Locations
More Related Trials
-
Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging
NCT03759236 ·Status: COMPLETED ·Phase: NA
-
Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students
NCT07266857 ·Status: RECRUITING
-
Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination
NCT02145156 ·Status: COMPLETED ·Phase: NA
-
Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
NCT04920526 ·Status: UNKNOWN
-
Parents' HPV Stories
NCT06704308 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
NCT04199689 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
NCT01824537 ·Status: COMPLETED ·Phase: PHASE4
-
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination
NCT02537756 ·Status: COMPLETED ·Phase: NA
-
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
NCT03929172 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
NCT00339040 ·Status: COMPLETED ·Phase: PHASE2
-
Tailoring of Vaccine-Focused Messages: Disease Salience
NCT03002324 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
NCT00309166 ·Status: COMPLETED ·Phase: PHASE2
-
HPV Message Testing and Social Media Campaign
NCT03747302 ·Status: COMPLETED ·Phase: NA
-
HPV Vaccination Health-promotion Programme on Vaccine Acceptance and Uptake Among Female Adolescents
NCT04438291 ·Status: COMPLETED ·Phase: NA
-
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
NCT01984697 ·Status: COMPLETED ·Phase: PHASE3
-
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
NCT07301905 ·Status: RECRUITING ·Phase: NA
-
HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults
NCT04474821 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates
NCT01526551 ·Status: COMPLETED ·Phase: NA
-
Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness
NCT05006833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
NCT00513526 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women
NCT04270773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
NCT04722822 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
NCT06959563 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody
NCT01206556 ·Status: COMPLETED
-
Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination
NCT02003508 ·Status: COMPLETED